Fast Track Immunotherapeutic Development with MuScreen™


MuScreen, CrownBio's High Throughput Syngeneic In Vivo Screen for Evaluating Immunotherapies

Limited Volume - Spring Enrollment Ends 31 May 2018

  • Built upon our collection of validated and well-characterized syngeneic models, and leveraging detailed model checkpoint inhibitor benchmarking data, as well as RNAseq and optional FACS analysis information

  • Comprising of a predesignated syngeneic panel across a range of cancer types

  • Evaluate TGI with the Syngeneic Efficacy Screening Panel of 12 models

  • Models run on a large scale, preset schedule, with shared vehicle and common groups to improve efficiency, reproducibility, and cost-effectiveness

Choose MuScreen Over a Traditional In Vitro Study

  • An effective and accurate way to find the right model - particularly for combination studies

  • Large-scale, staggered screening to reduce variability from sources such as antibodies and mice

  • Improve efficiency and save study time by rapidly identifying markers or models 

  • Benefit from multiple clients sharing the results of vehicle and other common groups significantly reducing both the number of animals needed and associate costs

Request MuScreen Pricing